Dec 24 (Reuters) - Shares of Agios Pharmaceuticals (AGIO) jumped 18% on Wednesday after the U.S. Food and Drug Administration approved the expanded use of its drug for the treatment of a type of blood disorder.
The drug mitapivat is now approved as a treatment for patients with anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia, the company said late on Tuesday.
Thalassemia is an inherited blood disorder affecting the body's ability to produce hemoglobin and healthy red blood cells.
The drug, under the brand name Aqvesme, is expected to be available in late January next year, following the implementation of the required safety program.
Mitapivat was already approved by the U.S. FDA in 2022 to treat low red blood cell counts in adults with pyruvate kinase deficiency, under the brand name of Pyrukynd.
"The approval unlocks an additional $320 million in peak revenue opportunity layered atop the existing mitapivat franchise," Truist analyst Gregory Renza said.
The latest approval is based on a late-stage study in which patients receiving mitapivat showed a statistically significant increase in hemoglobin response compared to those on placebo.
Aqvesme will carry a boxed warning for liver function tests every four weeks during the first 24 weeks of treatment and advises against use in patients with cirrhosis, Renza added.
(Reporting by Siddhi Mahatole in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
RFK Jr. guts the US childhood vaccine schedule despite its decades-long safety record - 2Guns N' Roses 2026 Tour: How to get tickets, presale times, prices and more
- 3Europe’s Airlines Run Low on Fuel
- 4New ‘Cloud-9’ object could reveal the secrets of dark matter
- 5Terminal cancer diagnosis announced by JFK's granddaughter
- Instructions to Upgrade the Security Elements of Your Kona SUV
- Savvy Tips for Seniors Hyundai IONIQ EV
- Understanding Various Sorts of Financial balances: An Extensive Outline
- Senegal president signs tough new anti-LGBT law doubling jail terms
- Yes, NASA's launching Artemis 2 astronauts to the moon on April Fools' Day. It's not a joke.
- $30K Disability Scam Implodes After Surf Trip in Mexico
- Central African Republic's president sworn in for a third term after disputed election
- Share your pick for the tree that you love for its novel magnificence!
- Takeda's AI-crafted psoriasis pill succeeds in late-stage studies
